SARC037: A Phase I/II Study to Evaluate the Safety of Trabectedin in Combination With Irinotecan in Ewing Sarcoma Patients
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- John Glod, MD/PhD
National Cancer Institute (NCI)
Study Director - Patrick Grohar, MD/PhD
Children's Hospital of Philadelphia
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Children'S Hospital of Los Angeles
Los Angeles, California, United States
- National Cancer Institute
Bethesda, Maryland, United States
- Boston Children'S Hospital / Dana Farber Cancer Institute
Boston, Massachusetts, United States
- University of Michigan
Ann Arbor, Michigan, United States
- Children'S Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
- University of Pennsylvania
Philadelphia, Pennsylvania, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 5 Jan 2021
- Primary completion
- 24 Apr 2025
- Completion
- 24 Apr 2025
- Last update posted
- 17 Dec 2025
- Registered enrollment
- 37
- Registry id
- NCT04067115
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.